Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

83.21
+0.44500.54%
Post-market: 82.04-1.1650-1.40%18:05 EDT
Volume:733.66K
Turnover:61.04M
Market Cap:3.65B
PE:-76.87
High:84.50
Open:82.76
Low:81.95
Close:82.76
52wk High:85.25
52wk Low:48.20
Shares:43.88M
Float Shares:32.68M
Volume Ratio:0.78
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:10.53
PE(LYR):-52.33

Loading ...

Tarsus Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 05

Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged

TIPRANKS
·
May 04

Tarsus Pharmaceuticals Price Target Maintained With a $88.00/Share by HC Wainwright & Co.

Dow Jones
·
May 04

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

GlobeNewswire
·
Apr 30

Bank of America Securities Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Apr 29

Tarsus Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
Apr 29

Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating

MT Newswires Live
·
Apr 24

Tarsus Pharmaceuticals : Oppenheimer Cuts Target Price to $98 From $105

THOMSON REUTERS
·
Apr 24

Shoucheng Invests in Embodied AI Leader TARS to Deepen Robotics Push

TIPRANKS
·
Apr 16

A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins

Simply Wall St.
·
Apr 02

Tarsus Pharmaceuticals (TARS) Receives a Buy from LifeSci Capital

TIPRANKS
·
Apr 01

Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity

TIPRANKS
·
Apr 01

Tarsus Pharmaceuticals Doses First Participant in Phase 2 Lyme Disease Prevention Study

MT Newswires Live
·
Mar 31

BRIEF-Tarsus Doses First Participant In Calliope, A Phase 2 Clinical Trial Of Tp-05 (Lotilaner)

Reuters
·
Mar 31

Tarsus Pharmaceuticals Inc - Enrollment to Complete in 2026 Tick Season, Topline Results Expected First Half 2027

THOMSON REUTERS
·
Mar 31

Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Mar 30

Analysts’ Top Healthcare Picks: Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 28

Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating

MT Newswires Live
·
Mar 26

Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho

TIPRANKS
·
Mar 26

Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Mar 26